Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

8.530 +0.900 (+11.80%)

Streaming Delayed Price Updated: 12:59 PM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

31 32 Next >

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Psychedelic Drug Stocks Index Up In December; Down YTD ↗

December 27, 2023

The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.

Via Talk Markets

Do Psychedelic Treatments Always Require Psychotherapy? Well, We Need To Look 'Beyond Reductionism' ↗

December 19, 2023

The question of whether psychedelic treatments always require psychotherapy is one hotly debated among researchers, and answers -as well as backstories- vary throughout the whole spectrum.

Via Benzinga

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗

December 18, 2023

Biden To Decide On Psychedelic Therapy Bill

Via Benzinga

Psychedelic Drug Stocks Index Declined 1.6% This Week ↗

December 17, 2023

Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.

Via Talk Markets

Topics ETFs

Compass Pathways: A Higher-Risk But Potentially Higher-Reward Company In The Biotech Arena ↗

December 16, 2023

If you can afford it – and if it would not be too big a position in your portfolio – putting $2,000 into a couple of speculative biotechs might be a good idea here. One I like is Compass Pathways.

Via Talk Markets

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗

December 11, 2023

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy

Via Benzinga

5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week ↗

December 10, 2023

The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.

Via Talk Markets

Compass Pathways appoints Teri Loxam as Chief Financial Officer

December 07, 2023

From Compass Pathways

Via GlobeNewswire

Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective, AMA Study Finds ↗

December 06, 2023

A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provi

Via Benzinga

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

December 06, 2023

Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression

From Compass Pathways

Via GlobeNewswire

Investing in Mental Health: 3 Stocks in the Wellness Space ↗

December 05, 2023

Mental health stocks can be a great addition to your portfolio as its importance becomes increasingly recognized.

Via InvestorPlace

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex ↗

December 02, 2023

The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November.

Via Talk Markets

La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday ↗

November 30, 2023

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday.

Via Benzinga

Topics Stocks

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

GH Research, Compass Pathways Among Top Psychedelic Movers Of Today ↗

November 23, 2023

Via Benzinga

GH Research Drags Down Psychedelic Drug Stocks Index By 7% ↗

November 23, 2023

The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week.

Via Talk Markets

UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center ↗

November 15, 2023

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life...

Via Benzinga

Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026 ↗

November 14, 2023

Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers:

Via Benzinga

Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday ↗

November 14, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter...

Via Benzinga

Topics Stocks

Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗

November 12, 2023

Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?

Via Benzinga

Topics Initial Public Offering

Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart ↗

November 11, 2023

Our Psychedelic Drug Stocks Index continues to exhibit extreme volatility, declining 8% this week, jumping 22% the previous week and falling 6.5% the week before that. This week's decline is based on...

Via Talk Markets

Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗

November 06, 2023

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

Via Benzinga

Topics Economy

Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22% ↗

November 05, 2023

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances.

Via Talk Markets

Compass Pathways Plc (CMPS) Q3 2023 Earnings Call Transcript ↗

November 03, 2023

CMPS earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

COMPASS Pathways Q3 2023 Results: Cash Injection To Sustain Phase 3 Psilocybin Program ↗

November 02, 2023

COMPASS Pathways plc (NASDAQ: CMPS), the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30, showing:

Via Benzinga

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

November 02, 2023

From COMPASS Pathways

Via GlobeNewswire

Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗

October 29, 2023

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Via Benzinga

Topics Intellectual Property

COMPASS Pathways announces CFO transition

October 26, 2023

From COMPASS Pathways

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.